Refixia (nonacog beta pegol) is a protein pharmaceutical. Nonacog beta pegol was first approved as Refixia on 2017-06-02. It has been approved in Europe to treat hemophilia b.
Trade Name |
Refixia |
Common Name |
Nonacog beta pegol |
Indication |
hemophilia b |
Drug Class |
Pegylated compounds |